| scholarly article | Q13442814 |
| P50 | author | Benoit I Giasson | Q88244471 |
| P2093 | author name string | Yong Ran | |
| Todd E Golde | |||
| Paramita Chakrabarty | |||
| Brenda D Moore | |||
| Jess-Karan S Dhillon | |||
| Cara Riffe | |||
| P2860 | cites work | A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. | Q54031652 |
| A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease | Q64796863 | ||
| The synucleins | Q24551013 | ||
| Mechanism of Anti-α-Synuclein Immunotherapy | Q26772943 | ||
| Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies | Q27322513 | ||
| Alpha-synuclein and neurodegenerative diseases | Q28204386 | ||
| Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system | Q28594502 | ||
| Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease | Q28740551 | ||
| Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials | Q30578913 | ||
| Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. | Q30585365 | ||
| Comparison of ethanol versus formalin fixation on preservation of histology and RNA in laser capture microdissected brain tissues | Q33203703 | ||
| Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations | Q33836384 | ||
| Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models | Q33865366 | ||
| The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. | Q34148223 | ||
| The biochemistry of Parkinson's disease | Q34426026 | ||
| Amyloid-ß-directed immunotherapy for Alzheimer's disease | Q34548700 | ||
| Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease | Q35058359 | ||
| E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment | Q35266392 | ||
| Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration | Q35542169 | ||
| Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy | Q35544737 | ||
| Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation | Q35700288 | ||
| Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice | Q35903351 | ||
| Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice | Q35946149 | ||
| Insights into prion strains and neurotoxicity | Q36856446 | ||
| Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission | Q37117527 | ||
| Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases | Q37119983 | ||
| Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions | Q37148311 | ||
| Structural and functional characterization of two alpha-synuclein strains | Q37305236 | ||
| Molecular mechanisms of alpha-synuclein neurodegeneration | Q37309838 | ||
| Transmission of multiple system atrophy prions to transgenic mice | Q37353012 | ||
| Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of α-Synuclein Fibrils | Q37560714 | ||
| Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy | Q37586721 | ||
| First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers | Q37664213 | ||
| The propagation of prion-like protein inclusions in neurodegenerative diseases | Q37759499 | ||
| Vaccination for Parkinson's disease | Q37968018 | ||
| The amyloid state of proteins in human diseases | Q37994283 | ||
| Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies | Q38079317 | ||
| Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases | Q38185934 | ||
| Active immunization therapies for Parkinson's disease and multiple system atrophy | Q38564102 | ||
| Cellular Uptake of α-Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of α-Synuclein and Mediated via Fcγ Receptors | Q38787483 | ||
| Cellular response of human neuroblastoma cells to α-synuclein fibrils, the main constituent of Lewy bodies | Q38827784 | ||
| Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. | Q38961743 | ||
| α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model | Q39138968 | ||
| Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice | Q39188281 | ||
| Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment | Q40117145 | ||
| T cells from patients with Parkinson's disease recognize α-synuclein peptides | Q40163812 | ||
| A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease | Q40433173 | ||
| MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration | Q41894807 | ||
| Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy | Q42493792 | ||
| Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease | Q44769508 | ||
| Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy | Q46124320 | ||
| Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease | Q46593989 | ||
| Role of alpha-synuclein carboxy-terminus on fibril formation in vitro | Q47762431 | ||
| 100 years of Lewy pathology | Q48278741 | ||
| Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. | Q48494226 | ||
| Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy | Q48544275 | ||
| Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. | Q48581887 | ||
| Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. | Q48619578 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Synuclein | Q24767155 |
| P304 | page(s) | e0184731 | |
| P577 | publication date | 2017-09-14 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies | |
| P478 | volume | 12 |
| Q64266885 | Comparative analyses of the in vivo induction and transmission of α-synuclein pathology in transgenic mice by MSA brain lysate and recombinant α-synuclein fibrils |
| Q55003043 | Differential induction of mutant SOD1 misfolding and aggregation by tau and α-synuclein pathology. |
| Q91429961 | Dissecting α-synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis |
| Q57458019 | Physiological carboxy-truncation of α-synuclein potentiates the prion-like formation of pathological inclusions |
| Q90275269 | Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier - phenotypic variability in autosomal dominant Alzheimer's disease |
| Q58700515 | Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study |
| Q93060745 | Unique α-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression |
Search more.